Bernadette Connaughton
Known title: DirectorCIK: 0001662521
Associated companies
Transaction History
| HALO | ▼ Sell | Open Market | 1,626 | $167K | 8/10/2026 | View on chart |
| HALO | ▼ Sell | Open Market | 1,000 | $76K | 7/1/2026 | View on chart |
| HALO | ▼ Sell | Open Market | 625 | $48K | 7/1/2026 | View on chart |
| HALO | ▼ Sell | Open Market | 1,625 | $108K | 6/1/2026 | View on chart |
| HALO | ▲ Buy | Grant | 6,796 | $0 | 5/5/2026 | View on chart |
| HALO | ▼ Sell | Open Market | 1,625 | $103K | 5/1/2026 | View on chart |
| HALO | ▼ Sell | Open Market | 2,000 | $141K | 1/5/2026 | View on chart |
| HALO | ▼ Sell | Open Market | 829 | $59K | 12/1/2025 | View on chart |
| HALO | ▼ Sell | Open Market | 2,000 | $137K | 11/10/2025 | View on chart |
| HALO | ▼ Sell | Open Market | 1,500 | $113K | 10/1/2025 | View on chart |
| HALO | ▼ Sell | Open Market | 500 | $38K | 10/1/2025 | View on chart |
| HALO | ▼ Sell | Open Market | 100 | $7K | 9/2/2025 | View on chart |
| HALO | ▼ Sell | Open Market | 2,977 | $219K | 9/2/2025 | View on chart |
| HALO | ▼ Sell | Open Market | 923 | $68K | 9/2/2025 | View on chart |
| HALO | ▲ Buy | Grant | 4,165 | $0 | 5/1/2025 | View on chart |
| HALO | ▲ Buy | Grant | 6,501 | $0 | 4/25/2024 | View on chart |
| HALO | ▲ Buy | Grant | 8,065 | $0 | 5/5/2023 | View on chart |
| HALO | ▼ Sell | Gift | 5,998 | $0 | 11/16/2022 | View on chart |
| HALO | ▲ Buy | Grant | 6,206 | $0 | 5/5/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 5, 2026
Halozyme Adds Jim Daly to Board Amid Q2 Earnings Review
Halozyme Therapeutics has appointed Jim Daly to its Board of Directors, a move that signals continued focus on governance and long-term strategy. This update arrives alongside a broader market review of the company's Q2 performance relative to other therapeutics firms. The stock is currently trading above its average analyst target price, with recent technical data showing confirmation near key support levels.
Halozyme Adds Jim Daly to Board Amid Q2 Earnings Review. Halozyme Therapeutics has appointed Jim Daly to its Board of Directors, a move that signals continued focus on governance and long-term strategy. This update arrives alongside a broader market review of the company's Q2 performance relative to other therapeutics firms. The stock is currently trading above its average analyst target price, with recent technical data showing confirmation near key support levels.